⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

EB is a group of inherited skin fragility disorders — not just one disease. There are four major types (simplex, junctional, dystrophic, Kindler), each caused by different gene mutations affecting different layers of the skin. The type determines severity, complications, and treatment approach.
There are now two FDA-approved gene therapies for EB. Beremagene geperpavec (Vyjuvek), approved in 2023, is a topical gel for dystrophic EB that delivers a working copy of the COL7A1 gene directly to wounds; its label was expanded in September 2025 to cover patients from birth and to allow at-home application by patients/caregivers. In April 2025, prademagene zamikeracel (Zevaskyn) became the first cell-based gene therapy for recessive dystrophic EB — gene-corrected sheets of the patient’s own skin, grafted surgically in a single application. These are genuine breakthroughs after decades with no disease-modifying treatment.
Wound care is the cornerstone of daily EB management. Proper bandaging, blister lancing, infection prevention, and pain management consume hours daily and profoundly affect quality of life. Learning expert wound care techniques is essential.
Squamous cell carcinoma is a life-threatening risk in severe EB. Patients with recessive dystrophic EB (RDEB) have a markedly elevated risk of aggressive squamous cell carcinoma developing in chronic wounds, often appearing in the 20s or 30s. Regular skin surveillance and prompt biopsy of suspicious wounds are critical.
Nutrition is a medical priority, not an afterthought. EB patients lose protein and calories through chronic wounds, often have difficulty eating due to oral and esophageal involvement, and frequently develop iron-deficiency anemia. A dietitian experienced with EB is essential.
Birch bark extract (Filsuvez) is approved for wound treatment. Approved by the EMA in 2022 and FDA in 2023 for junctional and dystrophic EB wounds, it is the first topical drug specifically approved for EB wound healing.
Get to an EB center. EB is rare and complex. Care at a center with multidisciplinary EB expertise dramatically improves outcomes, reduces complications, and connects families to clinical trials and support networks.
DEBRA is the essential patient organization. DEBRA (Dystrophic Epidermolysis Bullosa Research Association) operates internationally, providing patient support, funding research, and connecting families. Contact them early: debra.org.

▼ Collapse

Understanding Epidermolysis Bullosa

Epidermolysis bullosa (EB) is a group of rare inherited disorders in which the skin is extremely fragile and blisters easily from minor friction or trauma. In healthy skin, proteins act as anchors between the outer layer (epidermis) and the underlying layer (dermis). In EB, genetic mutations cause these anchoring proteins to be absent, reduced, or dysfunctional, so the skin layers separate and form painful blisters and wounds.

EB is sometimes called “butterfly skin” because the skin is described as being as fragile as a butterfly’s wing. The severity varies enormously — from mild blistering of the hands and feet to devastating whole-body involvement with life-threatening complications affecting the eyes, mouth, esophagus, and internal organs.

EB is present from birth or early infancy in most cases. It is not contagious, not caused by anything the parents did, and cannot be “caught.” It is a genetic condition, meaning it is caused by changes in DNA that are either inherited from parents or arise as new (de novo) mutations.

Approximately 1 in 20,000 live births worldwide
An estimated 30,000 people in the United States live with EB
EB simplex is the most common type, accounting for roughly 70% of cases
Dystrophic EB accounts for approximately 25% of cases
Junctional EB accounts for approximately 5% and includes the most severe forms
Kindler EB is the rarest type
EB affects all racial and ethnic groups equally

Skin has three main layers:

Epidermis (outer layer): The protective barrier you can see and touch.
Basement membrane zone (BMZ): A thin but critical layer of specialized proteins that anchors the epidermis to the dermis. This is where EB occurs.
Dermis (inner layer): Contains blood vessels, nerves, and connective tissue.

Different EB types involve different proteins in the basement membrane zone:

EB simplex: Blistering occurs within the epidermis (keratin 5 and 14 proteins)
Junctional EB: Blistering occurs at the junction between epidermis and dermis (laminin-332, type XVII collagen)
Dystrophic EB: Blistering occurs below the basement membrane, in the upper dermis (type VII collagen — anchoring fibrils)
Kindler EB: Blistering can occur at multiple levels (kindlin-1 protein)

The deeper the level of blistering, the more scarring results, and the more severe the complications tend to be.

The most important concept in this guide: EB is not one disease. The specific type and subtype, determined by genetic testing, defines the expected course, complications, and treatment approach. Genetic diagnosis is essential and should be pursued for every EB patient.

Your Action Clock — The First Weeks After Diagnosis

A time-phased checklist. The dates are general guidance drawn from DEBRA International best-practice care pathways (Mellerio et al. 2020); your EB team sets the exact schedule for your situation.

Within the first 48 hours: Contact an EB specialty center (see Specialty Centers) for handling and wound-care guidance, and reach out to DEBRA. For a newborn, ask staff to use no adhesive tape on the skin and to pad all contact surfaces.
Within the first week: Confirm that genetic testing has been ordered to identify the exact EB type, subtype, and gene. Ask: "Exactly which type and subtype of EB is this, and has genetic testing been ordered to confirm the gene?"
Within two weeks: Get a written daily wound-care regimen and a pain plan. Ask: "Can you write down my exact dressing regimen — which product goes on the wound, which goes on top, and how often to change it?"
In the first month: Have a nutrition assessment with a dietitian experienced in EB, plus baseline blood work (iron, zinc, vitamin D). Ask: "Are my iron, zinc, and vitamin D levels being checked, and do I need to see a dietitian?"
By month 3 and ongoing: Agree on a squamous cell carcinoma (SCC) surveillance schedule if the subtype is RDEB, and confirm that a referral to a multidisciplinary EB center is in place.

When to stop home care and seek urgent help the same day: spreading redness or warmth around a wound, fever, foul-smelling or discolored drainage, or a wound that suddenly becomes much more painful — these can signal a serious wound infection or sepsis.

Key Breakthroughs in EB

After decades with no disease-modifying treatments, the EB treatment landscape has changed significantly since 2022 with the first approved therapies:

FDA-APPROVED Beremagene geperpavec (Vyjuvek, also known as B-VEC) is the first gene therapy approved for any form of EB. It is approved for dystrophic EB (DEB) with COL7A1 mutations — originally for patients 6 months and older, and (since the September 2025 label update) for patients of all ages from birth. The therapy uses a modified herpes simplex virus type 1 (HSV-1) vector to deliver a functional copy of the COL7A1 gene directly to wound cells. When applied topically to EB wounds, the cells take up the gene and begin producing type VII collagen — the protein that is missing or dysfunctional in DEB. In the GEM-3 trial, 67% of Vyjuvek-treated wounds achieved complete closure at 6 months compared to 22% with placebo gel. It is applied weekly and, since the 2025 update, may be applied at home by patients or caregivers.

APPROVED (EMA/FDA) Filsuvez (birch bark extract, containing betulin as the active component) is a topical gel approved for the treatment of partial-thickness wounds in patients with junctional EB (JEB) and dystrophic EB (DEB). It was first approved by the EMA in June 2022 and subsequently by the FDA in December 2023. In the EASE trial, Filsuvez improved wound healing time compared to control gel. It works by promoting wound re-epithelialization through anti-inflammatory and wound-healing mechanisms. It is applied directly to wounds at each dressing change.

INVESTIGATIONAL / LIMITED USE Allogeneic hematopoietic stem cell transplant (HSCT) for severe RDEB was pioneered at the University of Minnesota. The rationale is that donor bone marrow cells can migrate to the skin, produce functional type VII collagen, and partially correct the underlying defect. Results have shown meaningful improvement in wound healing and skin integrity in some patients. However, the procedure carries significant risks including transplant-related mortality (historically 15–20% in early studies, improved with modified conditioning). It remains an option at a small number of specialized centers for the most severe cases.

INVESTIGATIONAL In a landmark 2017 case, a child with severe JEB had nearly 80% of his skin replaced with gene-corrected epidermal grafts. Stem cells were taken from a small area of his skin, the LAMB3 gene was corrected using a retroviral vector, and the corrected cells were grown into sheets of skin in a laboratory, then grafted onto his body. The child, who had been near death, survived and his regenerated skin remained stable years later. This proof-of-concept demonstrated that gene-corrected skin grafts can replace large areas of EB skin, though it has not yet been scaled to routine clinical use.

EB Types & Genetics

EB is classified into four major types based on where in the skin the blistering occurs. Each type has subtypes with varying severity. Understanding your specific type is essential for predicting complications and choosing treatments.

Type	Gene(s) / Protein	Inheritance	Key Features
EB Simplex (EBS)	KRT5, KRT14 (keratin 5, 14)	Autosomal dominant (most)	Most common (~70%). Blistering within the epidermis. Usually mildest form. Blisters mainly on hands, feet; may worsen with heat. Typically improves with age. Rare severe subtypes exist.
Junctional EB (JEB)	LAMB3, LAMA3, LAMC2 (laminin-332), COL17A1	Autosomal recessive	~5% of cases. Blistering at the dermal-epidermal junction. Severe generalized form (JEB-gen sev, formerly Herlitz) is the most severe EB type, often fatal in infancy. Intermediate JEB (formerly non-Herlitz) is less severe but still significant.
Dystrophic EB (DEB)	COL7A1 (type VII collagen)	Dominant (DDEB) or Recessive (RDEB)	~25% of cases. Blistering below the basement membrane. Recessive DEB (RDEB) is severe: scarring, contractures, mitten deformity of hands/feet, esophageal strictures, high SCC risk. Dominant DEB (DDEB) is generally milder.
Kindler EB	FERMT1 (kindlin-1)	Autosomal recessive	Rarest type. Blistering at multiple skin levels. Photosensitivity. Skin atrophy with age. Mucosal involvement (GI, urogenital). Blistering often improves with age but skin fragility persists.

Important: EB severity varies enormously even within the same type. Two children with the same genetic diagnosis can have very different experiences. Type and subtype guide expectations, but they do not predict individual outcomes with certainty. Genetic counseling is recommended for all EB families.

What specific type and subtype of EB do I/does my child have?
Has genetic testing been performed to identify the exact mutation?
What is the inheritance pattern, and what does this mean for other family members?
Should we have genetic counseling?
What complications should I watch for with this specific type?
Am I eligible for any gene therapy or clinical trials?
Is there a multidisciplinary EB clinic I should be referred to?
How often should I have skin cancer screening?

Diagnosis: The Tests You Need

EB is typically suspected based on the clinical appearance of skin fragility and blistering in a newborn or infant. Confirming the type and subtype requires specialized testing.

Immunofluorescence antigen mapping (IFM) is performed on a fresh skin biopsy taken from the edge of a new blister or from rubbed but unblistered skin. Fluorescent antibodies are used to identify the level of skin separation and the specific proteins present or absent. This test determines whether the blistering is within the epidermis (EBS), at the junction (JEB), or below the junction (DEB), and can identify which protein is affected.

TEM examines the ultrastructure of the skin at extremely high magnification. It can directly visualize structural abnormalities — such as absent or reduced anchoring fibrils in DEB, or abnormal hemidesmosomes in JEB. While less commonly used today due to the availability of genetic testing, it remains valuable when other tests are inconclusive.

Genetic testing is now the gold standard for EB diagnosis. It identifies the specific gene mutation causing EB, which:

Confirms the EB type and subtype definitively
Determines the inheritance pattern (important for family planning)
Predicts disease severity to some extent (e.g., null mutations typically cause more severe disease)
Determines eligibility for gene therapy (Vyjuvek requires COL7A1 mutations)
Enables prenatal or preimplantation genetic testing for future pregnancies

Next-generation sequencing panels covering all known EB genes are widely available. Turnaround time is typically 4–8 weeks.

Wound Care — The Foundation of EB Management

Daily wound care is the most time-consuming and important aspect of EB management. Proper technique reduces infection, minimizes scarring, promotes healing, and controls pain. Many families spend 2–4 hours per day on wound care for severe EB.

Lance blisters early. New blisters should be lanced (punctured) with a sterile needle to drain the fluid before they enlarge and cause more damage. The blister roof (top skin layer) should be left in place as a natural dressing.
Do not peel or debride the blister roof unless it is heavily contaminated or the wound beneath needs assessment.
Drain from the side. Insert the needle at the edge of the blister at a low angle. Press gently to express the fluid.
Hygiene. Clean hands, sterile needle, and clean workspace for every blister lancing.

Selecting the right dressings is critical. EB dressings must be non-adherent, provide moisture balance, and be comfortable. Key principles:

Primary (contact) layer: Non-adherent dressings such as Mepitel (silicone mesh), Adaptic, or Mepilex Lite. Never use standard gauze directly on EB wounds — it will adhere and cause further damage.
Secondary layer: Absorbent padding (e.g., soft gauze rolls, Mepilex foam) over the primary layer to absorb exudate.
Retention: Self-adherent wrap (Coban or similar) or tubular bandages (Tubifast). Never use adhesive tape directly on EB skin.
Frequency: Dressing changes typically every 1–3 days depending on wound drainage. Bathing before dressing changes can help soften and remove old dressings.

Lukewarm baths (not hot) help soften dressings for removal, clean wounds, and reduce bacterial load.
Add a small amount of table salt (approximately 1/4 to 1/2 cup per tub) or use a gentle cleanser to approximate normal saline concentration.
Some families add dilute bleach (1/4 cup household bleach per full bathtub) 2–3 times per week to reduce bacterial colonization, particularly with recurrent infections.
Soaking time: 15–30 minutes. Longer soaking helps remove adherent dressings.
Pat dry gently — never rub.

EB wounds are chronically colonized with bacteria and at constant risk of infection. Signs of wound infection include:

Increasing redness, warmth, or swelling around a wound
Foul odor or change in wound drainage (purulent, green, or brown)
Increased pain at the wound site
Fever
Delayed healing or wound deterioration

Topical antimicrobials (medical-grade honey such as Medihoney, polyhexamethylene biguanide [PHMB], silver-containing dressings) are commonly used. Topical mupirocin may be used for specific infections. Systemic antibiotics are reserved for clinical infection (cellulitis, spreading redness, fever).

Avoid: Prolonged use of topical antibiotics to reduce resistance risk. Iodine-based products should be used cautiously due to potential thyroid effects with large wound surface areas.

Key principle: The goal of EB wound care is to create a moist wound environment that protects fragile new skin while preventing infection. Too dry = painful, cracking skin. Too wet = maceration and infection risk. Finding the balance takes practice and expert guidance.

What specific dressings do you recommend for my/my child’s wounds?
Can I get a wound care nurse to help train me in proper technique?
How do I recognize the difference between colonization and true infection?
Is my child a candidate for Vyjuvek (gene therapy) or Filsuvez (birch bark extract)?
How often should dressing changes be done?
What pain management should be used before dressing changes?
Are there any wound care supplies covered by my insurance?
Should I be using bleach baths or antimicrobial rinses?

Pain & Itch Management

Pain and itching are among the most burdensome symptoms in EB. They are often undertreated. Both acute pain (from blistering, wound care, dressing changes) and chronic pain (from ongoing wounds, scarring) require active management.

Before dressing changes: Oral acetaminophen (typically 15 mg/kg per dose) or ibuprofen (10 mg/kg per dose) given 30–60 minutes before, per DEBRA/Mellerio 2020 EB pain guidance. For severe pain, stronger analgesics may be needed. Sucrose solutions for infants.
During dressing changes: Distraction techniques (videos, music, storytelling), optimal positioning, allowing the patient control over the process when possible.
Chronic pain: Gabapentin or pregabalin for neuropathic pain. Low-dose tricyclic antidepressants. Psychological support including cognitive behavioral therapy.
Topical: Lidocaine-based products can help with specific wound pain. Apply to intact skin surrounding painful wounds.
Non-pharmacologic: Warm (not hot) baths, music therapy, relaxation techniques, physical therapy, occupational therapy.

Itching in EB can be severe and debilitating. It disrupts sleep, causes scratching that creates new wounds, and significantly reduces quality of life.

First-line: Non-sedating antihistamines (e.g., cetirizine 10 mg once daily in adults, loratadine) during the day; sedating antihistamines (hydroxyzine, diphenhydramine) at night. Discontinue if there is no reduction in itch after a reasonable trial, and ask your team about gabapentin, which is often more effective for EB-related itch.
Second-line: Gabapentin or pregabalin (particularly effective for EB-related itch). Doxepin (topical or oral).
Topical: Cooling moisturizers, menthol-containing creams, colloidal oatmeal baths.
Keep skin moisturized: Dry skin increases itching. Emollients (white soft paraffin, coconut oil, specialized EB moisturizers) applied to unblistered skin.
Environmental: Keep the room cool; dress in loose, soft cotton clothing; use soft bedding.

Nutrition & Gastrointestinal Care

Nutritional challenges are a major source of morbidity in EB, especially in junctional and dystrophic forms. Chronic wounds create constant protein and calorie loss. Oral and esophageal blistering can make eating painful or impossible.

High protein: EB patients need significantly more protein than normal to support wound healing. Target 115–200% of normal protein requirements.
High calorie: Chronic wound healing is metabolically expensive. Caloric supplementation is often needed.
Iron supplementation: Iron-deficiency anemia is nearly universal in severe EB due to chronic blood loss from wounds and poor iron absorption. Oral iron is often insufficient; IV iron infusions may be needed.
Zinc: Important for wound healing. Deficiency is common in EB. Supplement with zinc sulfate or gluconate.
Vitamin D: Deficiency is common due to limited sun exposure (wounds, bandaging, photosensitivity in Kindler EB). Supplemented routinely — commonly 1000–4000 IU/day of cholecalciferol, adjusted to blood levels (EB nutrition guidance, Mellerio et al. 2020).
Vitamin C: Supports collagen synthesis and wound healing.
Fiber and fluids: Constipation is extremely common in EB due to reduced mobility, opioid use, and anal blistering. Adequate fiber, fluids, and stool softeners are essential.

Oral blistering: Blisters on the tongue, gums, palate, and inside of cheeks can make eating painful. Soft, cool foods are tolerated best. Avoid sharp, crunchy, or acidic foods.
Microstomia: Progressive scarring can reduce mouth opening in DEB, making dental care and eating increasingly difficult.
Dental caries: EB patients have very high rates of dental decay due to enamel defects, difficulty brushing, and soft food diets. Regular dental care with an EB-experienced dentist is essential.
Esophageal strictures: In RDEB, repeated esophageal blistering leads to narrowing (strictures) that can cause dysphagia (difficulty swallowing) and food impaction. Endoscopic balloon dilatation may be needed. Strictures may recur.
Gastrostomy (G-tube): When oral intake is insufficient despite optimization, a feeding tube placed directly into the stomach can be life-saving for maintaining nutrition. This is common in severe JEB and RDEB.

Is my child growing appropriately for their age?
Should we see a dietitian experienced with EB?
Does my child need iron studies, and could IV iron be beneficial?
Are vitamin D, zinc, and other levels being monitored?
Should we consider a gastrostomy tube for supplemental feeding?
How often should esophageal dilatation be considered?
What dental care plan do you recommend?

Complications of EB

EB can affect virtually every organ system. The severity and range of complications depend on the EB type. Understanding potential complications enables early detection and intervention.

Critical warning: Patients with recessive dystrophic EB (RDEB) have a dramatically elevated risk of aggressive squamous cell carcinoma. By age 55, the cumulative risk exceeds 90% in RDEB-sev gen. SCC in EB is often more aggressive than typical skin cancer and is the leading cause of death in RDEB.

SCC typically develops in areas of chronic wounds or scarring, often on the extremities
Metastasis is more common and more rapid than in non-EB SCC
Any wound that is not healing, looks different from other wounds, is growing rapidly, has raised or rolled edges, or bleeds easily should be biopsied immediately
Ask: "This wound has not healed in three months and looks different from my others — should it be biopsied to rule out skin cancer?"
Regular full-body skin examinations by a dermatologist experienced with EB are essential, starting in adolescence for RDEB patients
Treatment typically involves wide surgical excision; amputation may be necessary for limb SCC
Chemotherapy and immunotherapy (cemiplimab) are used for advanced/metastatic SCC

In RDEB, repeated blistering and scarring of the fingers and toes leads to fusion (pseudosyndactyly) and contractures, creating a “mitten” deformity that progressively reduces hand function. This is one of the most disabling complications of severe RDEB.

Prevention: Daily finger wrapping with individual finger dressings to prevent skin-to-skin contact and fusion. Silicone finger separators. Occupational therapy to maintain range of motion.
Surgical release: Surgical separation of fused fingers can restore function temporarily, but recurrence is common. Multiple surgeries over a lifetime may be needed.

Eyes: Corneal abrasions and blistering can cause pain, light sensitivity, and scarring. Regular ophthalmology exams. Lubricating eye drops. Avoid rubbing eyes.
Ears: External ear canal blistering can cause conductive hearing loss. Regular audiology assessments.
Airway: Laryngeal and tracheal involvement can cause hoarseness and, in severe cases, airway obstruction. This is rare but requires monitoring.

Anemia: Chronic blood loss from wounds plus chronic inflammation leads to severe anemia of chronic disease plus iron deficiency. Require regular monitoring and aggressive iron replacement (often IV).
Osteoporosis: Limited mobility, poor nutrition, low vitamin D, and chronic inflammation all contribute. DEXA scans should be performed. Bisphosphonates may be needed.
Renal disease: Chronic renal disease can develop in EB from a combination of amyloidosis, chronic infections, and nephrotoxic medications. Regular kidney function monitoring is essential.
Cardiomyopathy: Dilated cardiomyopathy has been reported, particularly in RDEB, likely related to chronic anemia, iron overload from transfusions, and selenium/carnitine deficiency.

Gene Therapy for EB

Gene therapy aims to correct the underlying genetic defect in EB, rather than just treating symptoms. After decades of research, the first gene therapy received FDA approval in 2023, and several more are in development.

FDA-APPROVED (May 2023)

Indication: Dystrophic EB (DEB) with COL7A1 mutation(s), for wounds. Originally approved for ages 6 months and older; the FDA expanded the label in September 2025 to include patients from birth.
Mechanism: A non-replicating HSV-1 viral vector carrying a functional copy of the COL7A1 gene. Applied topically to wounds. The viral vector delivers the gene to wound cells, which then produce type VII collagen.
Key trial (GEM-3, NCT04491604): Randomized, placebo-controlled. 67% of Vyjuvek-treated wounds achieved complete closure at 6 months vs. 22% with placebo. Statistically significant improvement in wound healing.
Administration: Applied weekly to selected wounds. As of the September 2025 label update, patients or caregivers may apply Vyjuvek at home (it no longer must be applied by a healthcare provider), with added flexibility for dressing changes. The gel is spread on the wound surface and covered with a non-adherent dressing.
Safety: Generally well-tolerated. Most common side effects were local wound reactions (itching, redness). The HSV-1 vector is non-replicating and does not cause herpes infection, but patients should be monitored for symptoms.
Limitations: Treats individual wounds, not all skin. Gene expression is transient, requiring repeated application. Long-term durability data still being collected.
Cost and assistance: Vyjuvek is one of the most expensive medicines in the world. Krystal Biotech set the launch list price at $24,250 per vial; at a commonly cited average of about 26 vials per year, that works out to roughly $631,500 per year before discounts, and more for patients with a heavy wound burden (Krystal Biotech launch pricing; figures as of July 2026). The sticker price is not the final word on access — the manufacturer’s KrystalConnect program offers a $0 copay program for eligible commercially insured patients (up to $15,000 per year in copay assistance) plus a Patient Assistance Program that may provide Vyjuvek at no cost to eligible uninsured or underinsured patients (KrystalConnect, vyjuvek.com, as of July 2026). Ask: "Are my COL7A1 mutations confirmed, am I a candidate for Vyjuvek, and can KrystalConnect help with the cost?"

FDA-APPROVED

Zevaskyn (prademagene zamikeracel, “pz-cel”; from Abeona Therapeutics; previously studied as “EB-101”) was FDA-approved on April 29, 2025 — the first and only cell-based gene therapy for recessive dystrophic EB (RDEB). A small skin biopsy is taken, the cells are genetically corrected in the laboratory to make working type VII collagen, grown into sheets of skin, and then surgically grafted onto the patient’s chronic wounds in a single application. Unlike Vyjuvek (a topical gel that delivers the gene to existing wound cells and is re-applied), Zevaskyn creates permanently gene-corrected skin in one procedure.

Who it’s for: adults and children with RDEB (confirmed COL7A1 mutations), applied to selected large or persistent wounds.
Key trial (VIITAL, NCT04227106): a single application achieved meaningful wound healing and pain reduction sustained over months.
Practical notes: it is a surgical, one-time-per-wound therapy delivered at qualified treatment centers (e.g., Stanford), and is high-cost; discuss eligibility with your EB specialist. Vyjuvek, Zevaskyn, and Filsuvez are not used together on the same wound.
The “Butterfly Child” case: In 2017, a boy with severe JEB (LAMB3 mutation) had ~80% of his skin replaced with gene-corrected epidermal grafts that remained intact for years — an early proof-of-concept for the gene-corrected-skin approach now realized in Zevaskyn.

Is Vyjuvek appropriate for my/my child’s wounds?
How do I access Vyjuvek, and is it covered by my insurance?
Are there any gene therapy clinical trials I should consider?
What are the realistic expectations for gene therapy — which wounds can be treated?
Are there any risks I should know about?
How long does the effect of Vyjuvek last?

Other Emerging Therapies

APPROVED (EMA 2022 / FDA 2023)

Indication: Partial-thickness wounds in JEB and DEB patients aged 6 months and older
Mechanism: Betulin (from birch bark) has anti-inflammatory and wound-healing properties. Promotes keratinocyte migration and re-epithelialization.
Key trial (EASE, NCT03068780): Randomized, vehicle-controlled. Showed faster wound closure with Filsuvez compared to control gel.
Use: Applied at every dressing change as a thin layer on wounds. Can be used alongside standard dressings.
Safety: Generally well-tolerated. Local wound reactions may occur.

INVESTIGATIONAL / LIMITED USE

HSCT for RDEB aims to provide donor-derived cells that can migrate to the skin and produce functional type VII collagen. Pioneered at the University of Minnesota.

Studies have shown improvements in wound healing, blister formation, and overall skin integrity in some patients
Benefits may take months to appear and tend to be partial rather than curative
Significant risks: transplant-related mortality (reduced with improved conditioning regimens but still present), graft-versus-host disease, infections during immunosuppression
Best outcomes seen in young children transplanted early, before extensive scarring develops
Not standard of care — considered on a case-by-case basis at specialized centers

INVESTIGATIONAL

Recombinant type VII collagen (PTR-01): Intravenous infusion of recombinant human type VII collagen for RDEB. Early trials showed that IV-delivered C7 localizes to the dermal-epidermal junction. Phase II/III trials have been conducted.
Cell-based therapies: Injection of fibroblasts or mesenchymal stem cells into EB wounds to provide local collagen production. Several small studies have shown temporary benefit.
Gene editing (CRISPR/Cas9): Preclinical and early clinical work on using CRISPR to directly correct EB-causing mutations in patient cells. Not yet in clinical use but represents a future direction.
Gentamicin (readthrough therapy): The aminoglycoside antibiotic gentamicin can cause readthrough of premature stop codon mutations, producing some functional protein. Topical gentamicin has shown some evidence of type VII collagen restoration in RDEB patients with nonsense mutations. Not FDA-approved for this indication.

Clinical Trials — Finding and Enrolling

Clinical trials are critically important in EB because the therapeutic pipeline is growing rapidly, and trials offer access to emerging gene therapies, protein replacement, and novel wound care approaches.

Trial / Agent	Approach	Population	NCT Number
GEM-3 (Vyjuvek)	Topical gene therapy (HSV-1 COL7A1)	DEB, age 6 months+ (basis of FDA approval)	NCT04491604
EASE (Filsuvez)	Topical birch bark extract	JEB and DEB (basis of EMA/FDA approval)	NCT03068780
Zevaskyn / EB-101 (VIITAL)	Gene-corrected skin grafts (surgical)	RDEB (basis of FDA approval)	NCT04227106 (Completed)
KB103 (early Vyjuvek study)	Topical gene therapy (HSV-1 COL7A1), Phase 1/2	DEB	NCT03536143 (Completed)
PTR-01 (recombinant C7)	IV protein replacement	RDEB	NCT04599881 (Completed — Phase 1/2 proof-of-concept)
FCX-007 (dabocemagene autoficel)	Gene-modified fibroblasts (injected)	RDEB	NCT04213261; earlier study NCT02810951
PTW-002 gel	Topical gene-silencing gel	Dominant or recessive DEB	NCT05529134
Gentamicin (readthrough)	Topical / IV, restores some collagen VII	RDEB with nonsense (stop-codon) mutations	Topical NCT02698735; IV NCT03392909
Diacerein 1% ointment	Anti-inflammatory topical	EB simplex	NCT03389308 (Completed)
Allogeneic MSC (ALLO-ASC-DFU)	Mesenchymal stem cell dressing	DEB	NCT02579369 (Completed)
HSCT + MSC for severe EB	Allogeneic bone marrow transplant	Severe RDEB (young children)	NCT01033552 (Completed — University of Minnesota)
RDEB natural-history registry	Observational (no drug)	RDEB	NCT01019148

Trial list dated as of July 2026. Status changes — confirm current recruitment and eligibility on ClinicalTrials.gov and with your EB center. Ask: "Which of these trials, if any, am I eligible for based on my exact subtype and mutations?"

ClinicalTrials.gov (clinicaltrials.gov): Search for “epidermolysis bullosa” and filter by status (recruiting) and location.
DEBRA International (debra-international.org): Maintains a clinical trials database and can help connect patients with relevant trials.
EB Research Partnership (ebresearch.org): US-based EB research foundation; trial information and connections.
Your EB center: Academic EB centers often run or participate in trials. Ask your dermatologist about available trials.
EB-CLINET: European EB clinical network with trial information.

International Access & Regulatory Landscape

EB drug approvals and availability vary by country.

Drug	US FDA	EMA (Europe)	Health Canada	Notes
Vyjuvek (beremagene geperpavec)	Approved May 2023; expanded to birth Sep 2025	Approved Apr 2025 (from birth)	Under review	First topical gene therapy for DEB. Also approved in Japan (Jul 2025). No longer US-only.
Zevaskyn (prademagene zamikeracel)	Approved Apr 2025 (RDEB)	Not yet submitted	Not yet submitted	First cell-based gene therapy for RDEB; surgically applied. US-approved to date.
Filsuvez (birch bark extract)	Approved Dec 2023	Approved June 2022	Under review	EMA approved first. Available in EU member states.
HSCT for EB	Not approved (investigational)	Not approved (investigational)	Not approved	Available at select centers as compassionate/experimental use.

DEBRA International: The global EB patient organization; publishes clinical practice guidelines and coordinates care standards
EB-CLINET: European EB Clinical Network of reference centers
NICE (UK): Technology appraisals for EB treatments
Mellerio et al. (2020): Best Practice Guidelines for Skin and Wound Care in EB
DEBRA of America: US-based patient support, research funding, advocacy
DEBRA UK: UK patient support and EB community nursing service
DEBRA Australia: Australian EB patient organization

Failed & De-Adopted Therapies

Understanding what has been tried and did not work helps families evaluate new claims and avoid treatments with no evidence of benefit.

FAILED Rigosertib, a PI3K/PLK pathway inhibitor, was explored as a treatment for SCC arising in EB patients. Clinical development did not demonstrate sufficient efficacy to support regulatory approval for this indication.

LIMITED BENEFIT Intradermal injection of allogeneic fibroblasts was investigated as a cell-based therapy for RDEB wounds. While some early studies showed temporary increases in type VII collagen at injection sites, the benefit was transient and not durable enough to change the disease course. The approach has largely been superseded by gene therapy strategies.

NOT EFFECTIVE Because EB simplex is a structural protein disorder, not an immune-mediated disease, systemic immunosuppressants (corticosteroids, methotrexate, cyclosporine) are not effective and expose patients to unnecessary side effects. They should not be used for any form of inherited EB (as distinct from EB acquisita, which is autoimmune).

WARNING Some unregulated clinics market “stem cell treatments” for EB with no published evidence of efficacy. These are often expensive and potentially dangerous. Legitimate EB stem cell research is conducted through regulated clinical trials at established medical centers. Always verify that any proposed treatment is part of a registered clinical trial (ClinicalTrials.gov) or an approved therapy.

Why this matters: EB families are understandably desperate for treatments, which makes them vulnerable to unproven claims. Before trying any treatment not recommended by your EB team, ask: “Is this supported by published peer-reviewed evidence, and is it available through a regulated clinical trial?”

Am I/is my child eligible for Vyjuvek gene therapy?
Should we consider bone marrow transplant, and what are the risks vs. benefits?
Are there any clinical trials we should consider?
What new therapies are in the pipeline for our specific EB type?
How should we be screening for squamous cell carcinoma?
Is there a protein replacement trial available?
What is the evidence for the treatment being proposed?

Specialty Centers

EB is rare and complex. Care at a center with multidisciplinary EB expertise — dermatology, wound care nursing, genetics, nutrition, ophthalmology, dentistry, occupational therapy, psychology, and surgery — significantly improves outcomes and quality of life.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

University of Utah Health — Dermatology

Academic dermatology program with expertise in genodermatoses and complex wound care

Location: 30 N 1900 E, Salt Lake City, UT 84132
Phone: 801-581-2121
Programs: Dermatology and dermatopathology services, genetic skin disease evaluation, wound care coordination, connection to Huntsman Cancer Institute for SCC surveillance.

Primary Children’s Hospital

Intermountain Health pediatric facility with pediatric dermatology and wound care

Location: 100 N Mario Capecchi Dr, Salt Lake City, UT 84113
Phone: 801-662-1000
Programs: Pediatric dermatology, neonatal care for EB newborns, multidisciplinary care coordination including nutrition, occupational therapy, and ophthalmology.

Huntsman Cancer Institute (HCI) — University of Utah

Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112
Phone: 801-585-0303
Programs: NCI-designated Comprehensive Cancer Center. Relevant for SCC surveillance and treatment in RDEB patients. Cutaneous oncology program.

Intermountain Health

Phone: 801-442-2000
Programs: Broad network across Utah and the Intermountain West. Dermatology, wound care, nutrition services. Can coordinate with academic centers for complex EB care.

How to choose. University of Utah Dermatology for adult EB evaluation and genetic diagnosis. Primary Children’s Hospital for pediatric EB care. HCI for SCC screening in RDEB patients.

Information verified June 2026. Availability changes — confirm with each institution directly.

Stanford University — EB Clinic

Location: Stanford, CA · Phone: 650-723-6316
One of the leading EB centers in the US. Multidisciplinary EB clinic with dermatology, wound care, genetics, nutrition, and psychology. Active clinical trial program including gene therapy. Key site for Vyjuvek development.

Columbia University Irving Medical Center — EB Center

Location: New York, NY · Phone: 212-305-5293
Comprehensive EB program. Multidisciplinary clinic. Active in EB research and clinical trials.

Cincinnati Children’s Hospital — EB Center

Location: Cincinnati, OH · Phone: 513-636-4200
Major pediatric EB center with multidisciplinary clinic, research programs, and clinical trials.

University of Minnesota — EB / HSCT Program

Location: Minneapolis, MN · Phone: 612-624-6100
Pioneered hematopoietic stem cell transplant for severe RDEB. Leading research program for HSCT in EB. Multidisciplinary EB care.

Children’s Hospital of Philadelphia (CHOP)

Location: Philadelphia, PA · Phone: 215-590-1000
Pediatric dermatology with EB expertise. Genetic testing and counseling. Active clinical trials.

Northwestern University — EB Program

Location: Chicago, IL · Phone: 312-695-8106
Multidisciplinary EB clinic. Research program. Connection to clinical trials.

VA Dermatology Services

Adult veterans with EB can access dermatology and wound care through the VA system. For complex EB care requiring multidisciplinary coordination, VA Community Care referral to an academic EB center is recommended.

George E. Wahlen VA Medical Center (SLC): 801-582-1565 — Dermatology and wound care; can coordinate referral to University of Utah for EB-specific evaluation
Veterans should ask about Community Care authorization for EB-specialized centers outside the VA

VA Health Benefits: va.gov/health-care
VA Community Care: 1-877-881-7618

The Hospital for Sick Children (SickKids), Toronto

Location: 555 University Avenue, Toronto, ON M5G 1X8
Phone: 416-813-1500
Programs: Comprehensive pediatric EB program. Dermatology, genetics, wound care, nutrition. Research and clinical trials.

BC Children’s Hospital, Vancouver

Location: Vancouver, BC
Phone: 604-875-2345
Programs: Pediatric dermatology with EB expertise. Provincial referral center for rare skin diseases.

DEBRA Canada: debra.ca
Canadian Skin Patient Alliance: canadianskin.ca

International Centers of Excellence for EB

Great Ormond Street Hospital (GOSH), London, UK: One of the world’s leading pediatric EB centers. DEBRA UK EB community nursing service. Clinical trials.
EB House Austria (Salzburg): DEBRA Austria center. Comprehensive multidisciplinary EB care and research. EB-CLINET reference center.
Necker-Enfants Malades Hospital, Paris, France: French reference center for EB. Gene therapy research. Performed the landmark “Butterfly Child” skin graft case.
University of Freiburg, Germany: EB-CLINET reference center. Research on EB gene therapy and wound care.
National EB Centre, Santiago, Chile: Latin American reference center for EB care.

Caregiver Guidance

Caring for someone with EB is one of the most demanding caregiving roles imaginable. The daily wound care, pain management, nutritional challenges, and emotional toll affect the entire family.

Create a routine. Consistent daily wound care at the same time reduces anxiety for both the patient and caregiver.
Organize supplies. Keep all wound care supplies organized and easily accessible. Many families use a dedicated wound care cart or station.
Pre-medicate for pain. Give pain medication 30–60 minutes before dressing changes to ensure it takes effect.
Let the patient participate. Even young children can be given age-appropriate choices and control during wound care (e.g., choosing which wound to start with, holding supplies).
Bath before bandages. Bathing before dressing changes softens old dressings and makes removal less traumatic.
Cut dressings in advance. Pre-cutting dressings to the right sizes before starting saves time during the actual dressing change.

Clothing: Soft, seamless clothing (turned inside out if seams are rough). Avoid rough fabrics, labels, and tight waistbands. Specialized EB clothing is available from some organizations.
Footwear: Soft, well-fitting shoes with seamless socks. Custom orthotics may help redistribute pressure. Some patients find sheepskin boot liners helpful.
Temperature: Heat worsens blistering in many EB types. Keep rooms cool. Avoid prolonged sun exposure.
Handling infants: Never lift an EB infant under the arms. Support under the buttocks and behind the head/neck. Use thick padding (sheepskin or padded mattresses) in cribs and car seats.
School and play: Work with schools to accommodate EB needs (padded seating, avoidance of contact sports, access to wound care supplies, air conditioning).

Caregiver burnout is real and predictable. The physical and emotional demands of EB care are extraordinary. Seek help before you are exhausted.
Connect with other EB families. DEBRA organizations facilitate family connections, camps, and support groups. Other EB families understand in a way that no one else can.
Professional support. Mental health support for caregivers and patients should be considered part of standard EB care, not an optional extra.
Respite care. If available, respite services can provide temporary relief for primary caregivers. DEBRA may help arrange trained respite providers.
Financial assistance. EB care is expensive. DEBRA of America, EB Research Partnership, and other organizations offer financial aid, insurance navigation, and dressing supply assistance.

Pregnancy & Epidermolysis Bullosa

Pregnancy with epidermolysis bullosa (EB) is possible, and many people with EB have had successful pregnancies. However, pregnancy increases demands on the skin and body, and careful multidisciplinary planning is essential.

Genetic counseling and family planning

EB is a genetic condition. If you have EB or a family member does, understanding the inheritance pattern is important for family planning:

Dominant EB (EBS, EBS-Dowling-Meara, DDEB) — one copy of the mutated gene is enough to cause disease; each child of an affected parent has a 50% chance of inheriting EB.
Recessive EB (JEB, RDEB) — both parents must be carriers; each child has a 25% chance of having EB.
Preimplantation genetic testing (PGT) — for couples who carry EB-causing mutations, PGT during IVF can identify embryos that did not inherit the mutation before implantation. DebRA (debra.org) and your EB specialist can connect you with specialized centers that offer this service.
Prenatal diagnosis — chorionic villus sampling (CVS) or amniocentesis can test for EB mutations during pregnancy.

During pregnancy with EB

Skin changes — hormonal changes and increased weight during pregnancy may increase blistering. Track any new areas of fragility with your dermatologist. Nutritional support (high protein, high calorie) is especially important during pregnancy to support wound healing and fetal growth.
Anemia — EB-related chronic anemia may worsen during pregnancy; monitor hemoglobin and treat with iron supplementation or other measures as guided by your team.
Esophageal strictures — if you have RDEB with esophageal involvement, pregnancy-related changes (reflux, pressure) may worsen symptoms. Plan with your gastroenterologist and obstetrician for safe nutritional management.

Labor and delivery

Deliver at a center familiar with EB or that has been briefed by your EB team. Trauma during delivery (forceps, vacuum) should be avoided if possible. Non-adhesive padding and careful positioning are essential.
Discuss with your obstetrician whether vaginal delivery or caesarean is safer for your specific EB subtype and disease severity.
The newborn must be handled by staff trained in EB care from the moment of birth.

Medications during pregnancy

Doxycycline (used for wound infection prevention in EB) — avoid in pregnancy (causes fetal tooth discoloration and bone effects). Use alternative antibiotics (cephalexin, amoxicillin-clavulanate) as directed by your team.
Wound dressings — most standard EB wound dressings (silicone, foam, non-adhesive) are safe during pregnancy. Iodine-containing dressings: use with caution (theoretical thyroid suppression risk to fetus; use only when essential and inform your obstetrician).
Systemic immunosuppressants (cyclosporine, mycophenolate) — discuss with your EB specialist and obstetrician; some are contraindicated in pregnancy (mycophenolate) while others may be acceptable (cyclosporine, with monitoring).

What to Prioritize, by EB Subtype

EB is not one disease. The single most useful thing you can do is confirm your exact subtype by genetic testing, because it changes which complications you watch for and which treatments you can access. The priorities below are drawn from the DEBRA International best-practice guidelines (Mellerio et al. 2020) and the 2020 consensus reclassification (Has et al., Br J Dermatol 2020). Your team tailors them to you.

EB Simplex (EBS) — KRT5 / KRT14 (about 70% of EB)

Focus: friction and heat reduction on hands and feet, blister management, and foot care. Most EBS is milder and tends to improve with age.
Real levers: soft seamless footwear, foot soaks, keratolytics for thickened soles, and cooling. Heat and sweating are common blistering triggers.
Gene therapy note: Vyjuvek and Zevaskyn are for dystrophic EB (COL7A1), not EBS. A topical gene therapy for EBS (KB105, KRT14) has been studied in trials but is not approved.
Ask: "My subtype is EBS — which of my daily triggers (heat, friction, footwear) should we target first, and is a keratolytic right for my foot calluses?"

Junctional EB (JEB) — laminin-332 / COL17A1 (about 5%)

Focus: in severe generalized JEB (formerly Herlitz), the newborn period is a medical emergency: airway, nutrition, infection, and fluid balance. Get to an EB center immediately.
Watch for: hoarseness or noisy breathing (laryngeal involvement), granulation tissue, dental enamel defects, and anemia.
Filsuvez (birch triterpenes) is approved for JEB wounds; wound-healing gene therapy for JEB is investigational.
Ask: "Is this severe or intermediate JEB, what is the realistic outlook, and who coordinates airway and feeding for us?"

Dystrophic EB (DEB / RDEB) — COL7A1 (about 25%)

Focus: preventing hand contractures (mitten deformity), protecting nutrition, managing esophageal strictures, and — the priority that saves lives — squamous cell carcinoma (SCC) surveillance in recessive DEB from adolescence.
Access to gene therapy: DEB with confirmed COL7A1 mutations is the group eligible for Vyjuvek (topical, weekly) and, for RDEB, Zevaskyn (surgical gene-corrected grafts). Confirm your mutations.
Ask: "My subtype is RDEB — when do we start SCC skin surveillance, and are my COL7A1 mutations confirmed so we can discuss Vyjuvek and Zevaskyn?"

Kindler EB — FERMT1 (rarest)

Focus: sun protection (photosensitivity), gum and mucosal care, and long-term skin-cancer surveillance. Blistering often eases with age but skin fragility and mucosal problems persist.
Ask: "Given Kindler EB, what sun protection and mucosal-surveillance schedule do you recommend?"

Medication & Dosing Reference (Plain-Language)

These are the medicines most often used in EB supportive care, with the doses commonly cited in the DEBRA/Mellerio 2020 EB pain, itch, and nutrition guidance. They are here so you can recognize what your team prescribes and ask informed questions — they are not instructions to self-treat. Pediatric doses are weight-based (per kilogram of body weight); your clinician sets the exact dose, maximum, and schedule.

Purpose	Medicine	Commonly cited dose	Notes
Pain before dressing changes	Acetaminophen (paracetamol)	15 mg/kg per dose (max 75 mg/kg/day)	Give 30–60 minutes before the dressing change.
Pain (moderate)	Ibuprofen	5–10 mg/kg per dose	Can be combined with acetaminophen for an additive effect.
Pain (severe / procedural)	Morphine (oral)	0.1–0.2 mg/kg before the procedure	For severe pain not controlled by non-opioids; watch for constipation. Sucrose 24% is used for infants.
Chronic pain & itch	Gabapentin	Titrated to about 5–15 mg/kg/day, divided	Often the most effective single agent for EB-related itch; titrate up over 2–4 weeks.
Itch (daytime)	Cetirizine	5–10 mg once daily	Non-sedating antihistamine; hydroxyzine 0.5–1 mg/kg at night when sedation helps sleep.
Iron-deficiency anemia	Ferrous sulfate (oral)	3–6 mg/kg/day of elemental iron	If oral iron is not enough, IV iron (ferric carboxymaltose or iron sucrose) is used. Target ferritin above 50 ng/mL.
Wound healing support	Zinc	1–2 mg/kg/day elemental zinc	Deficiency is common and slows healing.
Bone & immune health	Vitamin D (cholecalciferol)	1000–4000 IU/day, adjusted to blood level	Target 25-OH vitamin D above 30 ng/mL. Vitamin C 250–500 mg/day supports collagen.
Wound infection (skin/soft tissue)	Cephalexin (example antibiotic)	Pediatric ~25–50 mg/kg/day, divided	Choice depends on culture. Doxycycline (adults, 100 mg) is avoided in young children and pregnancy.

Nutrition & supplement targets

Nutrition is medical treatment in EB. These are the supplement doses and targets commonly cited in EB nutrition guidance (Mellerio et al. 2020); your dietitian adjusts them to blood levels.

Nutrient	Commonly cited target/dose	Why it matters in EB
Protein	2–3 g/kg/day (115–200% of normal)	Wounds drain protein continuously; healing demands more.
Elemental iron (oral)	3–6 mg/kg/day	Anemia is near-universal in severe EB.
IV iron (when oral fails)	e.g. ferric carboxymaltose up to 750–1000 mg per infusion	Overcomes poor gut absorption and chronic loss.
Zinc	zinc sulfate 220 mg (~50 mg elemental) or 1–2 mg/kg/day	Cofactor for wound healing; deficiency common.
Vitamin D (cholecalciferol)	1000–4000 IU/day	Bone health; low sun exposure from bandaging.
Vitamin C	250–500 mg/day	Collagen synthesis cofactor.
Calcium	500–1000 mg/day (age-adjusted)	Supports bone density alongside vitamin D.
Selenium	~55–70 mcg/day (check level)	Deficiency reported in RDEB; linked to heart-muscle problems.

Ask your team: "Can you write down each medicine, the exact dose for our weight, the maximum per day, and when to stop it if it is not helping?"

How EB Treatments Work Together

No single EB treatment works in isolation. The biggest gains come from stacking them — each one amplifies the others. Understanding these combined effects helps you spend your limited time and money where it matters most.

Vyjuvek and Filsuvez are applied onto wounds, so the condition of the wound bed determines how well they work. Controlling infection, keeping the wound moist (not too wet, not too dry), and gentle non-adherent dressings create the environment in which these drugs can act. The synergy is real: meticulous baseline wound care plus an approved wound therapy heals more than either alone.

Ask: "Before we start Vyjuvek, what should we do to prepare the wound so the gene therapy has the best chance to work?"

Chronic wounds drain protein, iron, and zinc; low levels of those then slow wound healing. Correcting iron-deficiency anemia, hitting protein targets (often 115–200% of normal), and restoring zinc and vitamin D produce a combined benefit — a well-nourished body closes wounds faster and responds better to every wound therapy you add on top. This is why an EB dietitian is not optional.

Pre-medicating with acetaminophen or ibuprofen 30–60 minutes before a dressing change, combined with distraction (video, music), soaking to loosen dressings, and letting the patient control the pace, gives more relief than medication alone. For itch, gabapentin combined with consistent skin hydration and a cool room amplifies the benefit and breaks the scratch-new-wound cycle.

Ask: "Can we build a combined pain plan — medicine plus soaking plus distraction — and write down the timing?"

Cost & Coverage — What EB Really Costs and Who Helps Pay

EB is one of the most expensive conditions to live with, and most of the cost is not the headline-grabbing gene therapies — it is the daily dressings. The figures below are dated and sourced so you can plan and push back on coverage decisions. Prices change; confirm current figures with the manufacturer, your specialty pharmacy, and your insurer.

Approved therapies

Therapy	Reported price	Assistance
Vyjuvek (beremagene geperpavec) — topical gene therapy, weekly	Launch list price about $24,250 per vial; at roughly 26 vials/year this is on the order of $631,500 per year before discounts (Krystal Biotech launch pricing, as of July 2026).	KrystalConnect: $0 copay for eligible commercially insured patients (up to $15,000/year in copay help) plus a Patient Assistance Program that may supply the drug at no cost to eligible uninsured/underinsured patients.
Zevaskyn (prademagene zamikeracel) — one-time surgical gene-corrected grafts (RDEB)	Wholesale acquisition cost of about $3.1 million per one-time treatment (Abeona Therapeutics, 2025) — among the most expensive therapies in the world. The real cost depends on how many wounds are treated.	Abeona offers a patient support program (case management, benefits investigation, outcomes-based agreements with payers). Ask your EB center to involve it early.
Filsuvez (birch triterpenes gel) — topical, at each dressing change	About $1,900 per 23.4 g tube (Drugs.com list price, 2026); monthly cost scales with the number of wounds treated.	Chiesi Total Care copay program: as little as $0 per prescription for eligible commercially insured patients; ask about the patient assistance pathway if uninsured.

The cost families actually hit: dressings and supplies

Dressings are the dominant lifetime cost of severe EB. Families managing extensive RDEB or JEB commonly report $5,000 to $10,000 or more per month in wound-care supplies (DEBRA and patient-reported), which can exceed $100,000 per year.
Individual items add up fast: silicone contact layers (Mepitel-type) and foam dressings (Mepilex-type) commonly run about $10 to $50 each at retail, and severe EB can use dozens per day.
Coverage path: most dressings are billed as durable medical equipment (DME) or through a wound-care supply benefit, not the pharmacy benefit. Ask for a letter of medical necessity from your EB team, and appeal denials — EB dressing needs are well documented in the literature.
Ask: "Can you write a letter of medical necessity listing my exact monthly dressing quantities, so my insurer or DME supplier covers them?"

Supply	Approx. US retail	Typical use in severe EB
Silicone contact layer (Mepitel-type), per sheet	about $10–$40	Several sheets per dressing change; multiple changes per week.
Foam dressing (Mepilex-type), each	about $15–$50	Secondary/absorbent layer over the contact layer.
Soft retention wrap / tubular bandage (roll)	about $5–$25	Holds dressings without adhesive.
Medical-grade honey / antimicrobial gel (tube)	about $15–$40	For colonized or slow-healing wounds.
Total monthly dressing/supply cost	about $5,000–$10,000+ (over $100,000/year in severe RDEB)	The dominant lifetime cost of EB — pursue DME coverage aggressively.

Other real costs

Genetic testing: an NGS EB gene panel commonly runs about $1,000 to $5,000, and is often covered or available at no charge through sponsored programs — ask your genetics team before paying out of pocket.
IV iron infusions and high-calorie/high-protein formula are recurring costs in severe EB; both are usually covered when medically documented.
Feeding tube (G-tube) placement, esophageal dilatation, and surgical procedures are hospital-billed; confirm pre-authorization.

Where to get help

DEBRA of America (debra.org) — free nurse navigator, wound-care-supply assistance, and insurance-navigation help.
EB Research Partnership (ebresearch.org) — research funding and family connections.
Manufacturer programs: KrystalConnect (Vyjuvek), Chiesi Total Care (Filsuvez), and Abeona's support program (Zevaskyn).
Broader copay/rare-disease help: the National Organization for Rare Disorders (rarediseases.org), PAN Foundation, HealthWell Foundation, and the Patient Advocate Foundation.
Public programs: Medicaid, SSI, and state Title V Children with Special Health Care Needs programs frequently cover children with severe EB — a hospital social worker can start the applications.
Ask: "Can your social worker help us apply to DEBRA's supply program and to Medicaid or Title V for our child?"

Verbatim Scripts for Key Conversations

Short, specific questions get better answers than open-ended ones. Copy these word-for-word into your next appointment. They are built around the decision points that matter most in EB care, per the DEBRA/Mellerio 2020 best-practice guidance.

At diagnosis

Ask: "Exactly which type and subtype of EB is this, and has genetic testing confirmed the gene and mutations?"
Ask: "Given this subtype, which complications should we watch for, and on what schedule?"

Wound care and dressings

Ask: "Can you write down my exact dressing regimen — which product touches the wound, which goes on top, and how often to change it?"
Ask: "How do I tell the difference between a wound that is just colonized and one that is truly infected and needs antibiotics?"
Ask: "Can I have a wound-care nurse train me in blister lancing and dressing technique?"

Gene therapy and access

Ask: "Are my COL7A1 mutations confirmed, and am I a candidate for Vyjuvek or, for RDEB, Zevaskyn?"
Ask your team: "Can you start the KrystalConnect or manufacturer support paperwork so cost is not the barrier?"

Cancer surveillance (RDEB)

Ask: "This wound has not healed in three months and looks different from my others — should it be biopsied to rule out skin cancer?"
Ask: "When do we start full-body skin surveillance for squamous cell carcinoma, and how often?"

Nutrition and daily life

Ask: "Are my iron, zinc, and vitamin D levels being checked, and do we need a dietitian or IV iron?"
Ask: "Should we consider a feeding tube before malnutrition sets in, rather than after?"
Ask your team: "Can your social worker help us apply to DEBRA's supply program and Medicaid?"

Evidence Snapshot & When to Stop a Treatment

The approved EB therapies each rest on a named, dated trial. Knowing the numbers helps you set realistic expectations and judge when something is working — or when it is time to stop.

What the trials showed

Vyjuvek (GEM-3 trial): in the pivotal trial (Guide et al., N Engl J Med, 2022), 67% of Vyjuvek-treated wounds fully closed at 6 months versus 22% with placebo gel — the basis of the FDA label (2023, expanded 2025).
Filsuvez (EASE trial): in the phase III trial (Kern et al., Br J Dermatol, 2023), 41.3% of wounds closed by day 45 versus 28.9% with control gel (per the FDA label, 2023).
Zevaskyn (VIITAL trial): a single surgical application of gene-corrected grafts produced durable wound healing and pain reduction, supporting the FDA label (2025).
Bone marrow transplant: the original RDEB transplant trial (Wagner et al., N Engl J Med, 2010) showed partial improvement but carried a roughly 15–20% transplant-related mortality — a serious trade-off, not a cure.

Honest framing: EB is not curable today. Vyjuvek, Zevaskyn, and Filsuvez improve wound healing — they do not correct the whole skin or reverse the disease. They are important tools, applied on top of expert wound care, nutrition, and complication surveillance.

Monitoring and stop rules — how to tell if a treatment earns its place

Wound therapies (Vyjuvek, Filsuvez): track specific wounds with photos and measurements. If a treated wound shows no meaningful progress toward closure after an adequate, agreed trial period, that is the signal to reassess with your team rather than continue indefinitely. Treat any wound infection first.
Itch medicines: give each a fair trial (for example, gabapentin titrated over 2–4 weeks). Discontinue if there is no reduction in itch after an adequate trial, and taper rather than stopping abruptly.
Antibiotics: reserved for true infection (spreading redness, fever, foul drainage), not routine colonization. There is a clear stop rule: complete the course, then stop — prolonged or prophylactic use breeds resistance.
Iron: re-check ferritin; the target is above 50 ng/mL. Continue only until stores are replete, then reassess — more is not better.
Ask: "For each treatment we start, what is the specific result we expect, by when, and what is the stop rule if we do not see it?"

Glossary

Anchoring fibrils: Structures made of type VII collagen that anchor the epidermis to the dermis. Absent or dysfunctional in dystrophic EB.
Autosomal dominant: Inheritance pattern where one copy of the mutated gene (from one parent) is sufficient to cause the condition.
Autosomal recessive: Inheritance pattern where two copies of the mutated gene (one from each parent) are needed to cause the condition.
Basement membrane zone (BMZ): The structural layer between the epidermis and dermis. The site of blistering in EB.
COL7A1: The gene encoding type VII collagen. Mutated in dystrophic EB. Target of Vyjuvek gene therapy.
DDEB: Dominant dystrophic EB. Generally milder form caused by dominant-acting COL7A1 mutations.
DEBRA: Dystrophic Epidermolysis Bullosa Research Association. International patient organization and advocacy group.
DEB: Dystrophic epidermolysis bullosa. Caused by COL7A1 mutations affecting type VII collagen.
Dermis: The inner layer of skin beneath the epidermis. Contains blood vessels, nerves, and connective tissue.
EBS: Epidermolysis bullosa simplex. The most common EB type, with blistering within the epidermis.
Epidermis: The outermost layer of skin. The protective barrier.
Gene therapy: Treatment that delivers a working copy of a gene to cells to correct a genetic defect. Vyjuvek is the first FDA-approved gene therapy for EB.
Hemidesmosomes: Structures that help anchor the epidermis to the basement membrane. Affected in junctional EB.
JEB: Junctional epidermolysis bullosa. Blistering at the dermal-epidermal junction. Caused by laminin-332 or COL17A1 mutations.
Keratin: Structural proteins in the epidermis. Keratins 5 and 14 are mutated in EB simplex.
Kindler EB: The rarest EB type, caused by FERMT1 mutations. Blistering at multiple skin levels with photosensitivity.
Laminin-332: A protein in the basement membrane zone. Mutations in its component genes (LAMA3, LAMB3, LAMC2) cause junctional EB.
Microstomia: Narrowing of the mouth opening due to scarring. Occurs in dystrophic EB.
Pseudosyndactyly: Fusion of fingers or toes due to scarring (“mitten deformity”). Occurs in severe RDEB.
RDEB: Recessive dystrophic EB. The more severe form of DEB, caused by recessive COL7A1 mutations.
SCC: Squamous cell carcinoma. A type of skin cancer with markedly elevated risk and aggressiveness in RDEB.
Type VII collagen: The protein forming anchoring fibrils. Missing or dysfunctional in dystrophic EB. The protein restored by Vyjuvek.
Vyjuvek: Brand name for beremagene geperpavec. The first FDA-approved gene therapy for EB — a topical gel for DEB (2023; expanded to all ages from birth in 2025).
Zevaskyn (prademagene zamikeracel): The first FDA-approved cell-based gene therapy for recessive dystrophic EB (April 2025) — gene-corrected sheets of the patient’s own skin, surgically grafted onto wounds in a single application.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, clinical practice guidelines, and expert consensus documents. Key sources are listed below.

Primary Resources

DEBRA International (debra-international.org) — Clinical practice guidelines, patient resources, research updates
DEBRA of America (debra.org) — Patient support, wound care education, financial assistance
EB Research Partnership (ebresearch.org) — Research funding and clinical trial connections
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
National Organization for Rare Disorders (NORD) (rarediseases.org) — Rare disease resources and patient assistance programs
Genetic and Rare Diseases Information Center (GARD) (rarediseases.info.nih.gov) — NIH-supported information on EB

Key Guideline and Research References

Best Practice Guidelines: Mellerio JE, El Hachem M, Engstrom P, et al. Updated Best Practice Guidelines for Skin and Wound Care in Epidermolysis Bullosa. DEBRA International, 2020.
GEM-3 Trial (Vyjuvek): Guide SV, Gonzalez ME, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022;387(24):2211–2219. (NCT04491604)
EASE Trial (Filsuvez): Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188(1):12–21. (NCT03068780)
VIITAL Trial (Zevaskyn / prademagene zamikeracel): Phase 3 study of autologous gene-corrected epidermal sheets in RDEB; basis of FDA approval (April 2025). (NCT04227106)
HSCT for RDEB: Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010;363(7):629–639.
Gene-corrected skin grafts: Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680):327–332.
EB classification: Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614–627.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

A practical test for any online claim: If a website is making a claim about EB treatment that does not appear anywhere in PubMed or DEBRA guidelines, that should be a significant warning sign.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose, type, or treat anyone. It does not know your specific mutations, EB subtype, wound burden, or individual circumstances. Only your medical team can build an actual care plan.
EB research is moving rapidly. Gene therapies, protein replacement, and other approaches are in active development. New approvals and trial results emerge regularly. Every time-sensitive fact should be re-verified with your team and primary sources.
Drug approvals and availability vary by country. This guide covers globally available information but focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, Canada, and other regions.
Individual experiences vary enormously. Even within the same EB type and subtype, severity and complications differ. Genetic counseling and expert clinical assessment are irreplaceable.
EB care is a marathon, not a sprint. This guide provides a snapshot. Long-term relationships with an experienced EB team, patient organizations, and other EB families are the foundation of living well with EB.

A final word. Living with EB requires extraordinary resilience from patients and families. For decades, there were no approved disease-modifying treatments — only wound care and supportive management. That has changed. The approval of Vyjuvek in 2023 marked the arrival of gene therapy for EB, and the pipeline of emerging treatments continues to grow. While a cure remains the ultimate goal, meaningful progress is real and accelerating. Connect with DEBRA, seek expert care, explore clinical trials, and know that the EB research and clinical community is working harder than ever. You are not alone.